Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy

Clinical Microbiology and Infection

Volumn 14, Issue 3, 2008, Pages 221-227

  Kuo, C P ^a   Wu, C L ^a   Ho, H T ^a   Chen, C G ^a   Liu, S I ^a   Lu, Y T ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cancer patients; Chemotherapy; Cytomegalovirus; Host responses; Reactivation; Symptoms

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEFITINIB; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HYPOPHARYNX CANCER; IMMUNE RESPONSE; INCIDENCE; LEUKOCYTE; LUNG CANCER; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; SCORING SYSTEM; SYMPTOM; TONGUE CANCER; VIRUS LOAD; VIRUS REACTIVATION;

CYTOMEGALOVIRUS;

EID: 38849199176     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01895.x     Document Type: Article

References (23)

1. Chemaly RF, Yen-Lieberman B, Castilla EA et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol 2004; 42: 2168-2172.
2. Limaye AP, Huang ML, Leisenring W et al. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis 2001; 183: 377-382.
3. Alberola J, Tamarit A, Cardenoso L et al. Longitudinal analysis of human cytomegalovirus glycoproteinB (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. J Med Virol 2001; 64: 35-41.
4. Han XY. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J Clin Microbiol 2007; 45: 1126-1132.
5. Wreghitt TG, Teare EL, Sule O et al. Cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2003; 37: 1603-1606.
6. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Clin Infect Dis 1990; 12: 754-766.
7. Piiparinen H, Hockerstedt K, Lappalainen M et al. Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients. J Clin Microbiol 2002; 40: 2945-2952.
8. Goossens VJ, Blok MJ, Christiaans MHL et al. Diagnostic value of nucleic-acid-sequence-based amplification for the detection of cytomegalovirus infection in renal and liver transplant recipients. Intervirology 1999; 42: 373-381.
9. Nguyen Q, Estey E, Raad I et al. Cytomegalovirus pneumonia in adults with leukemia: An emerging problem. Clin Infect Dis 2001; 32: 539-545.
10. Chemaly RF, Torres HA, Hachem RY et al. Cytomegalovirus pneumonia in patients with lymphoma. Cancer 2005; 104: 1213-1220.
11. Cope AV, Sabin C, Burroughs A et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176: 1484-1490.
12. Lucin P, Jonjic S, Messerle M et al. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol 1994; 75: 101-110.
13. Hengel H, Koszinowski UH, Conzelmann KK. Viruses know it all: New insights into IFN networks. Trends Immunol 2005; 26: 396-401.
14. Simon CO, Seckert CK, Dreis D et al. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 2005; 79: 326-340.
15. Fietze E, Prosch S, Reinke P et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58: 675-680.
16. Docke WD, Prosch S, Fietze E et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994; 343: 268-269.
17. Reddy V, Meier-Kriesche HU, Greene S et al. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 698-705.
18. Couriel D, Saliba R, Hicks K et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
19. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002; 14: 1393-1395.
20. Haerter G, Manfras BJ, de Jong-Hesse Y et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004; 39: 88-94.
21. Mizuta M, Schuster MG. Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2005; 40: 1071-1072.
22. Sandborn WJ. Biologic therapies should be used early in the treatment of Crohn's disease. AGA Perspectives 2006; 2: 4.
23. Sandherr M, Einsele H, Hebart H et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006; 17: 1051-1059.